



SARS-CoV-2 infection in the lungs of human ACE2 transgenic mice causes severe 1 
inflammation, immune cell infiltration, and compromised respiratory function 2 
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Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) emerged in late 2019 27 
and has spread worldwide resulting in the Coronavirus Disease 2019 (COVID-19) pandemic. 28 
Although animal models have been evaluated for SARS-CoV-2 infection, none have recapitulated 29 
the severe lung disease phenotypes seen in hospitalized human cases. Here, we evaluate 30 
heterozygous transgenic mice expressing the human ACE2 receptor driven by the epithelial cell 31 
cytokeratin-18 gene promoter (K18-hACE2) as a model of SARS-CoV-2 infection. Intranasal 32 
inoculation of SARS-CoV-2 in K18-hACE2 mice results in high levels of viral infection in lung 33 
tissues with additional spread to other organs. Remarkably, a decline in pulmonary function, as 34 
measured by static and dynamic tests of respiratory capacity, occurs 4 days after peak viral titer 35 
and correlates with an inflammatory response marked by infiltration into the lung of monocytes, 36 
neutrophils, and activated T cells resulting in pneumonia. Cytokine profiling and RNA sequencing 37 
analysis of SARS-CoV-2-infected lung tissues show a massively upregulated innate immune 38 
response with prominent signatures of NF-kB-dependent, type I and II interferon signaling, and 39 
leukocyte activation pathways. Thus, the K18-hACE2 model of SARS-CoV-2 infection 40 
recapitulates many features of severe COVID-19 infection in humans and can be used to define 41 
the mechanistic basis of lung disease and test immune and antiviral-based countermeasures.  42 
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Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the recently 45 
emerged RNA virus responsible for the Coronavirus Disease 2019 (COVID-19) pandemic. Clinical 46 
disease is variable, ranging from asymptomatic infection to multi-organ failure and death, with a 47 
case-fatality rate of ~5%. The binding of the SARS-CoV-2 spike protein to human angiotensin-I 48 
converting enzyme-2 (hACE2) targets the virus to type II pneumocytes within the lung, resulting 49 
in injury, inflammation, and subsequent respiratory distress1,2. Other COVID-19 manifestations 50 
(e.g. cardiac dysfunction, coagulopathy, and gastrointestinal tract symptoms) suggest that extra-51 
pulmonary sites of infection contribute to disease pathogenesis in some patients3. 52 
The development of countermeasures that reduce COVID-19 morbidity and mortality is a 53 
priority for the global research community, and animal models are essential for this effort. 54 
Although several animal species used in laboratory research have been evaluated for 55 
susceptibility to SARS-CoV-2 infection, none have recapitulated the severe disease seen in 56 
hospitalized human cases. Hamsters, ferrets, and non-human primates develop mild to moderate 57 
viral disease and recover spontaneously4,5. Conventional laboratory strains of mice cannot be 58 
infected efficiently by SARS-CoV-2 because hACE2 but not mouse ACE2 supports SARS-CoV-59 
2 binding6,7. Multiple strategies for introducing hACE2 into mice have been developed including 60 
(1) transient introduction of hACE2 via adenoviral viral vectors8, (2) expression of hACE2 as a 61 
transgene driven by heterologous gene promoters9,10, or  (3) expression of hACE2 by the mouse 62 
ACE2 promoter11,12. While these animals all support SARS-CoV-2 infection, none cause severe 63 
disease or lethality. Thus, an animal model is still urgently needed for understanding the biology 64 
of severe SARS-CoV-2 infection and evaluating the efficacy of countermeasures for COVID-19. 65 
 The K18-hACE2 transgenic (K18-hACE2) mice, in which hACE2 expression is driven by 66 
the epithelial cell cytokeratin-18 (K18) promoter13, were originally developed to study SARS-CoV 67 
pathogenesis and cause lethal infection9. Here, we evaluate heterozygous hACE2 transgenic 68 
mice as a model for severe COVID-19 disease. After intranasal SARS-CoV-2 inoculation, K18-69 
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hACE2 mice rapidly lost weight starting at 4 days post infection (dpi) and began to succumb to 70 
disease at 7 dpi. High levels of viral RNA and infectious virus were detected in the lungs of infected 71 
animals at 2, 4, and 7 dpi by RT-qPCR, in situ hybridization, and plaque forming assays. Infection 72 
was accompanied by declines in multiple parameters of pulmonary function, substantial cellular 73 
infiltrates in the lung composed of monocytes, neutrophils, and activated T cells, high levels of 74 
pro-inflammatory cytokines and chemokines in lung homogenates, and severe interstitial and 75 
consolidative pneumonia. Because of its severe disease and intense immune cell infiltration, the 76 
K18-hACE2 model of SARS-CoV-2 infection may facilitate evaluation of immunomodulatory and 77 
antiviral drugs against COVID-19 and our understanding of immune-mediated mechanisms of 78 
pathogenesis.  79 
 80 
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K18-hACE2 mice are highly susceptible to SARS-CoV-2 infection. We inoculated 8-83 
week-old heterozygous K18-hACE2 mice of both sexes via intranasal route with 2.5×104 PFU of 84 
SARS-CoV-2 (strain 2019n-CoV/USA_WA1/2020). Beginning at 4 days post-infection (dpi), K18-85 
hACE2 mice demonstrated marked weight loss, and by 7 dpi most animals had lost approximately 86 
25% of their body weight (Fig 1a), with many becoming moribund. High levels of infectious SARS-87 
CoV-2 (Fig 1b) and viral RNA (Fig 1c) were detected in lung homogenates at 2, 4, and 7 dpi, 88 
whereas lower levels were present in other tissues (e.g., heart, spleen, kidney). Virtually no viral 89 
RNA was measured in gastrointestinal tract tissues or in circulation until 7 dpi in the serum and 90 
colon, and this was only in a subset of animals (Fig 1d). The tissues supporting SARS-CoV-2 91 
infection in this model mirrored the pattern of hACE2 expression, with the highest receptor levels 92 
in the lungs, colon, kidney, and brain (Extended Data Fig 1a). Levels of hACE2 declined in the 93 
lung over the course of infection (Extended Data Fig 1b), suggesting either receptor 94 
downregulation, hACE2 shedding, or death of hACE2-expressing cells after SARS-CoV-2 95 
infection. A subset of infected K18-hACE2 mice had high levels of viral RNA and infectious virus 96 
in the brain (Fig 1d-e), consistent with previous reports with SARS-CoV and SARS-CoV-2 in 97 
hACE2 transgenic mice9,12,14. As no infectious virus and only low levels of viral RNA were detected 98 
in the brain of the majority (60%) of animals, the observed clinical disease is more consistent with 99 
lung and not brain infection. Staining for viral RNA in brain tissue by in situ hybridization showed 100 
that only one of six animals was positive at 7 dpi.; this animal had disseminated infection 101 
throughout the cerebral cortex with noticeable sparing of the olfactory bulb and cerebellum 102 
(Extended Data Fig 2).  103 
Histopathological changes in the lung after SARS-CoV-2 infection. Analysis of 104 
hematoxylin and eosin-stained lung sections from K18-hACE2 mice infected with SARS-CoV-2 105 
(Fig 2a) showed a progressive inflammatory process. At 2 dpi, we observed accumulation of 106 
immune cells confined predominantly to perivascular sites. By 4 dpi, these immune cell infiltrates 107 
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involved a greater area of the lung with focal collections into adjacent alveolar spaces with alveolar 108 
wall thickening. By 7 dpi, immune cells, including neutrophils and mononuclear cells were found 109 
throughout the lung in alveolar and interstitial locations along with interstitial edema and 110 
consolidation. To correlate histopathological findings with sites of SARS-CoV-2 infection, we also 111 
stained lung sections for viral RNA using in situ hybridization (Fig 2b). At 2 dpi, expression of 112 
SARS-CoV-2 RNA was localized predominantly to alveolar epithelial cells and a few airway 113 
epithelial cells. This pattern also was seen at 4 dpi, but with more diffuse spread throughout the 114 
lung. By 7 dpi, the level of viral RNA expression was diminished and associated with cellular 115 
debris and collapsed alveoli. No significant viral RNA signal was localized to immune cells. 116 
Together, these findings provide evidence of a progressive and widespread viral pneumonia with 117 
perivascular and pan-alveolar inflammation characterized by immune cell infiltration, edema, and 118 
lung consolidation.  119 
Extra-pulmonary histopathology after SARS-CoV-2 infection. We examined 120 
additional tissues implicated in the pathogenesis of severe COVID-19 in humans, including the 121 
brain, heart, liver, kidney, and spleen. Brain tissues of K18-hACE2 mice with minimal detectable 122 
SARS-CoV-2 infection appeared normal, whereas the one brain with a high level of infection at 7 123 
dpi showed multiple foci of inflammatory cells (e.g., neutrophils, lymphocytes, and monocytes) 124 
involving the meninges, the subarachnoid space, parenchymal blood vessels, and the brain 125 
parenchyma (Extended Data Fig 3a). Abnormalities were observed in 2 of 9 hearts at 4 dpi (e.g., 126 
scattered hypereosinophilic cardiomyocytes with pyknotic nuclei) and most livers at 4 and 7 dpi 127 
(e.g., areas of inflammatory cell infiltrates and hepatocyte loss) (Extended Data Fig 3b-c). In one 128 
kidney at 4 dpi, we observed focal acute tubular injury (Extended Data Fig 3d); otherwise, the 129 
kidneys showed no apparent abnormalities. The spleen in SARS-CoV-2-infected K18-hACE2 130 
mice appeared normal (Extended Data Fig 3e), and fibrin thrombi were not detected in any of 131 
the extra-pulmonary organs examined.  132 
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 Pathophysiology of SARS-CoV-2 infection. To assess for clinically-relevant changes in 133 
physiology over the course of SARS-CoV-2 infection in K18-hACE2 mice, we measured clinical 134 
chemistry and hematological parameters from peripheral blood samples (Fig 3). Plasma levels of 135 
sodium, potassium, and chloride concentrations and the anion gap all trended slightly downward 136 
at 7 dpi (Fig 3a-d) whereas plasma bicarbonate noticeably increased (Fig 3e), possibly as a result 137 
of poor gas exchange resulting from lung pathology or decreased respiratory drive. Other plasma 138 
analytes including calcium, glucose, and blood urea nitrogen were unchanged (Fig 3f-h). 139 
Hematocrit and plasma hemoglobin levels increased later in the course of infection, possibly 140 
because of reduced water intake and hemoconcentration (Fig 3i-j). We also observed a modest 141 
prolongation in the prothrombin time at 7 dpi that was preceded by an increase in D-dimer 142 
concentrations on 2 and 4 dpi (Fig 3k-l).  143 
We next examined the impact of SARS-CoV-2 infection on pulmonary and cardiac function 144 
using a treadmill stress-test to assess exercise tolerance (Fig 3m). Compared to mock-infected 145 
controls, at 4 dpi, a subset of SARS-CoV-2-infected K18-hACE2 mice began to show reduced 146 
exercise tolerance, as measured by decreased distance travelled. However, by 5 dpi, all infected 147 
K18-hACE2 mice had substantially reduced exercise tolerance compared to mock-infected 148 
animals or their own pre-infection baseline performance (Fig 3m).  149 
 To examine changes to the biophysical properties of the lung over the course of SARS-150 
CoV-2 infection, we mechanically ventilated mice via tracheostomy and performed several forced-151 
oscillation tests to determine various respiratory mechanics parameters (Fig 3n-w). Infected 152 
animals showed normal lung biomechanics at 2 and 4 dpi but had markedly abnormal values in 153 
most parameters at 7 dpi relative to mock-infected controls. These abnormalities included 154 
reduced inspiratory capacity as well as increased respiratory system resistance and elastance 155 
(Fig 3n-p). Collectively, these changes resulted in a downward deflection of the pressure-volume 156 
loop (Fig 3r) with concomitant decreases in static compliance (Fig 3q), the shape-describing K 157 
parameter (Fig 3s), and loop hysteresis (Fig 3t), which together indicate reduced lung compliance 158 
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and distensibility. Further analysis using broadband forced oscillation maneuvers15 revealed that 159 
SARS-CoV-2 infected mice at 7 dpi had relatively normal Newtonian resistance (Fig 3u), which 160 
is primarily a reflection of resistance in larger conducting airways. In contrast, mice at 7 dpi had 161 
marked increases in tissue damping (Fig 3v) and elastance (Fig 3w); these parameters measure 162 
the dissipation and storage of oscillatory energy in parenchymal tissue and reflect tissue and 163 
peripheral airway resistance and elastic recoil (i.e., tissue stiffness), respectively. The 164 
measurements of mechanical properties of the respiratory system suggest that SARS-CoV-2 165 
infection in K18-hACE2 mice predominantly causes disease in the alveoli and lung parenchyma, 166 
and not in the conducting airways, which is consistent with both our histopathological analysis in 167 
mice and measurements of pulmonary function in humans with viral pneumonia and respiratory 168 
failure including COVID-1916.  169 
The immune response to SARS-CoV-2 Infection in the lungs. An excessive pro-170 
inflammatory host response to SARS-CoV-2 infection is hypothesized to contribute to pulmonary 171 
pathology and the development of respiratory distress in some COVID-19 patients17. To evaluate 172 
the composition of the immune cell response in SARS-CoV-2-infected K18-hACE2 mice, we 173 
performed flow cytometric analysis on lung homogenates and bronchoalveolar lavage (BAL) fluid 174 
at three time points after intranasal virus inoculation (Fig 4a-b, Extended Data Fig 4). Consistent 175 
with our histopathological analysis, we observed increased numbers of CD45+ immune cells in 176 
the BAL beginning at 2 dpi and in the lung at 4 dpi. The cellular infiltrates at 4 and 7 dpi in the 177 
lung were composed principally of myeloid cell subsets including Ly6G+ neutrophils, Ly6C+ 178 
monocytes, and CD11b+CD11c+ dendritic cells. In the BAL fluid, monocyte numbers peaked at 4 179 
dpi, and levels of neutrophils and dendritic cells continued to rise through 7 dpi. Accumulation of 180 
monocytes in the BAL fluid coincided with a decrease in the number of tissue-resident alveolar 181 
macrophages, an observation consistent with scRNA-seq analysis of BAL fluid of patients with 182 
severe COVID-19 disease18,19. By 7 dpi, we also observed an increase in several lymphoid cell 183 
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subsets in the lung including NK1.1+ natural killer cells, γδ	CD3+ T cells, CD3+CD4+ T cells, 184 
CD3+CD8+ T cells, and activated CD44+CD3+CD8+ T cells (Fig 4a).  185 
 Extensive changes in cytokine profiles are associated with COVID-19 disease 186 
progression20-22. Compared to the lungs of uninfected K18-hACE2 control mice, we observed 187 
induction of Ifnb, Il28, Ifng, Cxcl10, Cxcl11, and Ccl2 mRNA over the first week (Fig 4c) with 188 
highest expression occurring at 2 dpi for all cytokines except Ifng and Ccl2. We also measured 189 
protein levels in the lungs using a multiplex assay of 44 different cytokines and chemokines (Fig 190 
4d, Extended Data Fig 5). Although mRNA expression was highest at 2 dpi, almost all up-191 
regulated pro-inflammatory cytokines (IFNβ, IL-6, CXCL10, CXCL9, CCL5, CCL12, TIMP-1, 192 
TNFα, and G-CSF), T cell-associated cytokines (IL-10, IFNγ, and IL-2), and myeloid cell-193 
associated chemokines (CCL2, CCL3, CCL4, CXCL1, and LIF) peaked at 7 dpi. These data are 194 
consistent with cytokine profiling of serum from human COVID-19 patients and transcriptional 195 
analysis of the BAL fluid of human patients, which showed that elevated levels of  IL-10, IL-6, IL-196 
2, IL-7, G-CSF, CXCL10, CCL2, CCL3, and TNF-α correlate with disease severity19,23-25. Overall, 197 
our data suggest that in the context of the inflammatory response to SARS-CoV-2 in the lungs of 198 
K18-hACE2 mice, many cytokines and chemokines are induced, with some having sustained 199 
expression and others showing rapid up-and down regulation patterns.  200 
Distinct transcriptional signatures are associated with early and late immune 201 
responses to SARS-CoV-2 infection. Studies in other small animals and humans have reported 202 
cytokine signatures coupled with delayed type I interferon (IFN) signaling or elevated IFN 203 
signatures in the lung26,27. To assess how the kinetics of infection and ensuing inflammation 204 
modulate the cytokine and IFN response to SARS-CoV-2, we performed RNA sequencing of lung 205 
homogenates of K18-Tg mice at 0 (mock), 2, 4, and 7 dpi. Principal component analysis (PCA) 206 
revealed distinct transcriptional signatures associated at 7 dpi (Fig 5a) with overlapping 207 
signatures at 2 and 4 dpi. Hundreds of genes were differentially expressed at all time points 208 
compared to mock-infected animals (Fig 5b), many of these associated with IFN signaling, NF-209 
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kB-dependent cytokine responses, or leukocyte activation. In agreement with the PCA, only 449 210 
differentially expressed genes were shared at all time points when compared to mock. In contrast, 211 
1,975 unique differentially expressed genes were identified between mock to 7 dpi whereas only 212 
59 and 152 genes were different between mock and 2 and 4 dpi, respectively (Fig 5c). Gene 213 
ontology analysis of the top upregulated genes at all time points showed enrichment of gene 214 
clusters in cytokine-mediated signaling, type I and II IFN signaling, neutrophil activation, and 215 
pathogen recognition receptor signaling (Fig 5d).  Upregulation of gene sets involved in cytokine-216 
mediated signaling, neutrophil activation, cellular responses to type II IFN, and toll-like receptor 217 
signaling were most pronounced at 7 dpi (Fig 5e-g, Extended Data Fig 6a-c, Supplementary 218 
Table 1). Of note, different genes in the type I IFN signaling pathway were upregulated at 2 and 219 
4 dpi (e.g., Irf9, Irf7, Stat1, and certain IFN-stimulated genes (ISGs) Isg15, Mx1, Oas3, Ifit1, Ifit2, 220 
and Ifit3) versus 7 dpi (e.g., Ifnar1/2, Tyk2, Irf1 and certain ISGs Samhd1, Oas2, and Ifitm1). This 221 
suggests a temporally distinct type I IFN response (Fig 5f), which has been described previously 222 
with IFNa and IFNb subtypes28-30. Alternatively, the differences in IFN and ISG signatures at early 223 
and late time points could reflect differential signaling contributions of type I and III IFNs, as these 224 
cytokines are both expressed in the lung after SARS-CoV-2 infection31 and induce overlapping 225 
yet non-identical sets of ISGs32. Collectively, the RNA sequencing data from the lungs of K18-226 
hACE2 mice show distinct immune signatures associated with early infection (days 2 and 4) and 227 
late (day 7) SARS-CoV-2 infection.  228 
  229 
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In this study, we found that SARS-CoV-2 infection of K18-hACE2 transgenic mice causes 231 
severe pulmonary disease. After intranasal SARS-CoV-2 inoculation, K18-hACE2 mice rapidly 232 
lost weight after 4 dpi and began to succumb to disease at 7 dpi. High levels of viral RNA and 233 
infectious virus were detected in the lungs of infected animals at 2, 4, and 7 dpi by RT-qPCR, in 234 
situ hybridization, and plaque assay. Infection was accompanied by high levels of pro-235 
inflammatory cytokines and chemokines in the lung and an impressive cellular infiltrate comprised 236 
primarily of monocytes, neutrophils, and T cells. The combined infection and inflammation 237 
resulted in severe interstitial pneumonia characterized by collapsed alveolar spaces. This caused 238 
detrimental changes in lung physiology including decreased exercise tolerance, reduced 239 
inspiratory capacity, and stiffening of the lung parenchyma.  240 
SARS-CoV-2 infection is subclinical or mild in most human cases. A small, yet clinically 241 
important fraction develop life-threatening disease requiring hospitalization and intensive care. 242 
Mild disease is a feature of SARS-CoV-2 infection in naturally susceptible animals including 243 
hamsters, ferrets, cats, and non-human primates5. This is perhaps unsurprising given that the 244 
strongest risk factors for developing severe COVID-19 in humans (e.g., old age, cardiovascular 245 
disease, and diabetes) are absent in many laboratory animals. Mild to moderate disease is seen 246 
in many rodent models of SARS-CoV-2 infection, including those expressing hACE2 via viral 247 
vectors or transgenes8,11,12,33. Thus, the severity of disease we observed following SARS-CoV-2 248 
infection of K18-hACE2 mouse is unique. As the onset of severe clinical disease in K18-hACE2 249 
mice occurs days after peak viral infection and is associated with high levels of infiltrating immune 250 
cells and inflammatory mediators in the lung, immune responses likely contribute to pathogenesis.   251 
The histopathological changes we observed in the infected lungs of K18-hACE2 mice 252 
correlate with the impaired pulmonary function. Pneumocytes become infected early, which led 253 
to recruitment of leukocytes into the pulmonary interstitium, production of proinflammatory 254 
cytokines, injury to parenchymal cells, collapse of the alveolar space, and compromise of gas 255 
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exchange, all of which could cause the hypercapnia we observed at 7 dpi. This course is 256 
remarkably consistent with human disease in which rapid early viral replication is followed by 257 
inflammatory responses, which are believed to contribute to pathology, morbidity, and mortality34.  258 
A fundamental understanding of the immunological processes that influence COVID-19 259 
disease is needed to select immunomodulatory interventions that target key cell types or 260 
pathways. We saw substantial immune cell accumulation in the lungs of K18-hACE2 mice, an 261 
observation consistent with post-mortem analysis of human patients35. Infiltrates were composed 262 
primarily of myeloid cells including monocytes and neutrophils as well as activated CD8+ T cells 263 
and corresponded with high levels of chemokines that drive their migration. The lymphopenia 264 
associated with severe COVID-19 in humans is attributed in part to the immune cell migration into 265 
inflamed tissues21,36. In transcriptional analyses of BAL fluid from infected humans with severe 266 
COVID-19, an accumulation of CD8+ T cells, neutrophils, and monocytes coincided with the loss 267 
of alveolar macrophages18,19. In our study, using cytokine analysis and RNA-sequencing of lung 268 
homogenates, we detected enhanced expression of several myeloid cell chemoattractants (e.g.,  269 
CCL2, CCL3, CCL4, CXCL1, and CXCL10) and other key inflammatory cytokines (TNFa, IL-6, 270 
and G-CSF) that correlate with COVID-19 disease severity in humans26,27. Given these parallel 271 
findings, studies in K18-hACE2 mice evaluating the role of specific immune pathways and cell 272 
subsets in disease pathogenesis could inform the selection of immunomodulatory agents for 273 
severe COVID-19.  274 
The role of type I IFN in SARS-CoV-2 pathogenesis in this model warrants further 275 
investigation, as it has been suggested that a dysregulated type I IFN response contributes to 276 
excessive immunopathology. Indeed, in SARS-CoV infection, type I IFN signaling appears pro-277 
inflammatory and not antiviral37. Our RNA sequencing analysis revealed differences in the type I 278 
IFN gene signatures associated with early and late SARS-CoV-2 infection. Given that ISGs can 279 
exert diverse functions apart from their antiviral activities, including inflammatory, metabolic, and 280 
transcriptional effects38, these two “early” and “late” ISG modules may have different functional 281 
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consequences following SARS-CoV-2 infection. Furthermore, how these temporally distinct 282 
programs are induced and regulated remains uncertain and may be the result of cell-type 283 
specificity, kinetics, and sensitivity to different type I or III IFN subtypes.  284 
The development of severe disease following SARS-CoV-2 infection is an important 285 
feature of the K18-hACE2 model, although the precise reason for this susceptibility compared to 286 
other hACE2 transgenic models remains unknown. Potential explanations include a high number 287 
of hACE2 transgene insertions (https://www.jax.org/strain/034860) and/or the strength and 288 
cellular specificity of the K18 promoter. Human ACE2 is expressed in multiple tissues in the K18-289 
hACE2 mouse9, which could allow for SARS-CoV-2 infection of multiple organs. While we 290 
detected viral RNA in several tissues, the lung was the most heavily infected and showed the 291 
most consistent and severe histopathological changes; these findings were anticipated given the 292 
known tropism of SARS-CoV-2 for the respiratory tract and the intranasal route of infection. 293 
Moderate levels of viral RNA also were found in the heart, kidney, and spleen, with peak titers at 294 
2 and 4 dpi, whereas levels in gastrointestinal tract tissues (duodenum, ileum, and colon) were 295 
lower. In the gastrointestinal tract of K18-hACE2 mice, hACE2 was expressed most abundantly 296 
in the colon, which correlated with infection seen at later time points. Although hACE2 is 297 
expressed in the gastrointestinal tract in other hACE2-expressing mice, productive infection was 298 
observed only upon intragastric inoculation or at early time points following intranasal 299 
infection11,12.  300 
We observed dichotomous SARS-CoV-2 infection in the brain, with high virus levels in 301 
approximately 40% of mice at 7 dpi, and low levels in the remaining 60% of animals. Infection of 302 
the brain also was observed in K18-hACE2 mice infected with SARS-CoV9,14 but occurred earlier 303 
(at 3 to 4 dpi) and more uniformly. Similar to the experiments with SARS-CoV, we did not detect 304 
SARS-CoV-2 in the olfactory bulb, which suggests that both SARS-CoV and SARS-CoV-2 cross 305 
the blood-brain barrier instead of traversing the cribriform plate and infecting neuronal processes 306 
near the site of intranasal inoculation39. Notwithstanding this data, and unlike SARS-CoV, 307 
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alterations in smell and taste are features of SARS-CoV-2 infection in humans40, suggesting that 308 
cell types within the olfactory system may be susceptible to infection or injury. More study is 309 
needed to clarify the routes SARS-CoV-2 dissemination throughout the host and particularly how 310 
it accesses the brain in some animals and humans.  311 
While SARS-CoV-2 lung infection in K18-hACE2 mice provides a model for studying 312 
severe infection that recapitulates features of COVID-19 in humans, we acknowledge several 313 
limitations. The expression of the hACE2 transgene is non-physiological in several respects. It is 314 
driven by a non-native (i.e., the cytokeratin-18) promotor, resulting in tissue expression levels that 315 
are distinct from endogenously-expressed ACE2. ACE2 expression in K18-hACE2 mice is 316 
independent of the complex regulatory systems that governs ACE2 levels41. As such, comorbid 317 
conditions (e.g., obesity, hypertension, diabetes) that alter ACE2 expression in humans41 likely 318 
cannot be modelled faithfully in this transgenic mouse.  319 
In summary, we found that SARS-CoV-2 infection of K18-hACE2 transgenic mice supports 320 
robust viral replication in the lung, which leads to severe immune cell infiltration, inflammation, 321 
and pulmonary disease. Thus, the K18-hACE2 mouse is an attractive small animal model for 322 
defining the mechanisms of the pathogenesis of severe COVID-19 and may be useful for 323 
evaluating countermeasures that reduce virus infection or associated pathological inflammatory 324 
responses. 325 
 326 
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FIGURE LEGENDS 360 
Figure 1. SARS-CoV-2 infection in K18-hACE2 mice. Eight to nine-week-old male and 361 
female K18-hACE2 transgenic mice were inoculated via the intranasal route with 2.5 x 104 PFU 362 
of SARS-CoV-2. a. Weight change was monitored (two experiments, n = 10; two-way ANOVA: 363 
*** P < 0.001, **** P < 0.0001, symbols represent the mean ± SEM). b-c. Viral burden in the lungs 364 
was analyzed at 2, 4 and 7 dpi by plaque assay for infectious virus (b) and qRT-PCR for viral 365 
RNA levels (c). d. Viral RNA levels in indicated tissues (heart, brain, kidney, spleen, serum, and 366 
gastrointestinal tract) at 2, 4, and 7 dpi as measured by qRT-PCR. e. Viral burden in the brains 367 
as measured by plaque assay (two experiments, n = 10). For b-e, bars represent the mean and 368 
the dotted line indicates the limit of detection.  369 
Figure 2. Histopathological analysis of SARS-CoV-2 infection in K18-hACE2 mice. 370 
a. Hematoxylin and eosin staining of lung sections from K18-hACE2 mice following mock infection 371 
or after intranasal infection with 2.5 x 104 PFU of SARS-CoV-2 at 2, 4, and 7 dpi. Images show 372 
low- (left; scale bars, 250 μm), medium- (middle; scale bars, 50 μm), and high-power 373 
magnification (right; scale bars, 25 μm). Representative images from n = 6 per group. b. SARS-374 
CoV-2 RNA in situ hybridization of lung sections from K18-hACE2 mice for conditions in (a). 375 
Images show low- (left; scale bars, 100 μm), medium- (middle; scale bars, 100 μm), and high-376 
power magnification (right; scale bars, 10 μm). Representative images from n = 6 per group. 377 
Figure 3. Functional consequences of SARS CoV-2 infection in K18-hACE2 mice. a-378 
k. Clinical chemistry and hematological parameters from the peripheral blood of mock-treated or 379 
SARS-CoV-2 infected animals at 2, 4, and 7 dpi (two experiments, n = 13-16 per group; one-way 380 
ANOVA with Dunnett’s test; * P < 0.05; *** P < 0.001; **** P < 0.0001, bars represent the mean, 381 
and the dotted line indicates the mean value of the mock-treated group). l. Serum D-dimer levels 382 
of mock-treated or SARS-CoV-2 infected animals at 2, 4, and 7 dpi (two experiments, n = 5 per 383 
group; one-way ANOVA with Dunnett’s test; * P < 0.05; *** P < 0.001; **** P < 0.0001, bars 384 
represent the mean, and the dotted line indicates the mean value of the mock-treated group). 385 
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Asterisks indicate statistical significance compared to mock infection. m. Results of a treadmill 386 
performance test as measured by the distance traveled in 6 minutes. (two experiments, n = 10; 387 
two-way ANOVA: **** P < 0.0001, symbols represent the mean ± SEM). n-w. Respiratory 388 
mechanics parameters from the lung function assessment in mock-treated or SARS-CoV-2 389 
infected male and female mice at 2, 4, and 7 dpi. Individual results with group mean are shown. 390 
n. Inspiratory capacity. o. Respiratory system resistance. p. Respiratory system elastance. q. 391 
Pressure-Volume (PV) loops. r. Static compliance. s. Shape parameter K. t. Hysteresis (Area). 392 
u. Newtonian resistance. v. Tissue damping. w. Tissue elastance (two experiments, n = 6-7 per 393 
group; one-way ANOVA with Dunnett’s test; * P < 0.05; *** P < 0.001; **** P < 0.0001, bars 394 
represent the mean and the dotted line indicates the mean value of the mock-treated group).  395 
Figure 4. The immune response to SARS-CoV-2 Infection in the lungs of K18-hACE2 396 
mice. a-b. Flow cytometric analysis of lung tissues (a) and bronchoalveolar lavage (b) at 2, 4, 397 
and 7 dpi post-SARS-CoV-2 infection (two experiments, n = 4-6 per group; one-way ANOVA; * P 398 
< 0.05; ** P < 0.01; *** P < 0.001, bars represent the mean and the dotted line indicates the mean 399 
value of the mock-treated group). Asterisks indicate statistical significance compared to mock 400 
infection. c. Fold change in gene expression of indicated cytokines and chemokines as 401 
determined by RT-qPCR, normalized to Gapdh, and compared to naïve controls in lung 402 
homogenates at 2, 4  and 7 dpi (two experiments, n = 9-11 per group). Dotted line indicates the 403 
average level of cytokine or chemokine transcript in naïve mice. d. Heat-maps of cytokine levels 404 
as measured by multiplex platform in lung tissue of SARS-CoV-2-infected mice at 2, 4, and 7 dpi. 405 
For each cytokine, fold-change was calculated compared to mock-infected animals and Log2(fold-406 
change) was plotted in the corresponding heat-map (two experiments, n = 9-11 per group, 407 
associated statistics are reported in Extended Data Fig 5). 408 
Figure 5. Distinct transcriptional signatures are associated with early and late 409 
immune responses to SARS-CoV-2 infection. RNA sequencing analysis from the lung 410 
homogenates of naive K18-hACE2 mice and at 2, 4, and 7 dpi (two experiments, n = 4-6 group) 411 
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a. Principal component analysis performed for 20 samples with the log2-transformed gene-level 412 
counts per million (log2cpm) data b. Volcano plots comparing differentially-expressed genes from 413 
samples taken at day 2 versus day 0, day 4 versus day 0, and day 7 versus day 0. Red and blue 414 
indicate upregulated (red) and downregulated (blue) genes that demonstrated a fold-change > 2 415 
and false discovery rate (q-value) < 0.05. The dashed horizontal lines mark a q-value of 0.05 and 416 
vertical lines indicate log2 fold-change of 1. Each dot in the volcano plots represents a single 417 
gene. c. Venn diagram of overlapping genes identified in differential expression analysis when 418 
comparing mock to 2, 4, and 7 dpi. Numbers in the parenthesis under each comparison indicates 419 
the total number of significantly differential genes followed by the proportion of the total that are 420 
up and down-regulated. d. GO Enrichment Analysis of biological process terms enriched in up-421 
regulated genes from comparisons of mice 2, 4, and 7 days dpi against mock-infected mice. 422 
Terms were ranked by the false discovery rate (q-value), and the top 20 are listed after eliminating 423 
redundant terms. e-g. Heat maps of significantly up-regulated genes during SARS-CoV-2 424 
infection enriched in cytokine-mediated signaling pathway (e), type I IFN signaling pathway (f), 425 
and cellular response to IFNg (g) identified through Gene Ontology analysis. Genes shown in 426 
each pathway are the union of the differentially expressed genes from the three comparisons (2, 427 
4, and 7 dpi versus mock-infected). Columns represent samples and rows represent genes. Gene 428 
expression levels in the heat maps are z score-normalized values determined from log2cpm 429 
values. 430 
 431 
EXTENDED DATA FIGURE LEGENDS 432 
Extended Data Figure 1. hACE2 expression in the K18-hACE2 model. a. mRNA 433 
expression levels of hACE2 in the lung, kidney, heart, brain, spleen, duodenum, colon, and ileum 434 
of naive K18 hACE2 mice (two experiments, n = 5). b. mRNA expression levels of hACE2 in the 435 
lungs of K18 hACE2 mice at 2, 4, and 7 dpi following SARS-CoV-2 infection (two experiments, n 436 
= 4 per time point, bars represent the mean value of each group).  437 
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Extended Data Figure 2. SARS-CoV-2 Infection in the brain. SARS-CoV-2 RNA in situ 438 
hybridization of brain sections from K18-hACE2 mice following intranasal infection with 2.5 x 104 439 
PFU of SARS-CoV-2 at 7 dpi. Images show low-power magnification (scale bars, 100 μm) with a 440 
high-power inset. One of six infected mice stained positively for viral RNA in the brain. Images 441 
are from this mouse and another that showed virtually no infection in the brain. 442 
Extended Data Figure 3. Extra-pulmonary histopathology after SARS-CoV-2 443 
infection. a-d. Hematoxylin and eosin staining of the brain (a), heart (b), liver (c), kidney (d), and 444 
spleen (e) from K18-hACE2 mice following mock infection or at 7 dpi. Scale bars indicate 200 μm. 445 
For a, microscopic images show inflamed vessels with extravasation of immune cells into the 446 
brain parenchyma, microglial activation, and subarachnoid inflammation with involvement of the 447 
underlying parenchyma. The dashed box indicates the location of two higher power magnification 448 
images below.   449 
Extended Data Figure 4. Flow cytometric analysis. Flow cytometric gating strategy for 450 
BAL and lung tissue analysis.  451 
 Extended Data Figure 5. Cytokine induction following SARS-CoV-2 Infection. 452 
Cytokine levels as measured by multiplex platform in lung tissue of SARS-CoV-2-infected mice 453 
at 2, 4, and 7 dpi (two experiments, n = 9-11 per group; one-way ANOVA with Dunnett’s test; * P 454 
< 0.05; ** P < 0.01; *** P < 0.001, bars represent the mean value of each group). 455 
Extended Data Figure 6. Transcriptional immune signatures following SARS-CoV-2 456 
infection. a-c. Heat maps of significantly upregulated genes during SARS-CoV-2 infection 457 
enriched in neutrophil activation pathways (a), Toll-like receptor signaling pathway (b), and 458 
negative regulation of viral genome replication (c) identified through Gene Ontology analysis. 459 
Genes shown in each pathway are the union of differentially expressed genes from the three 460 
comparisons (2, 4, and 7 dpi versus mock-infected). Columns represent samples and rows 461 
represent genes. Gene expression levels in the heat maps are z score-normalized values 462 
determined from log2 [cpm values]).  463 
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Supplementary Table 1. Lists of up-regulated genes enriched in cytokine-mediated 464 
signaling pathway, type I IFN signaling pathway, cellular response to IFNg, neutrophil activation 465 
pathways, toll-like receptor signaling pathways, and negative regulation of viral genome 466 
replication identified through Gene Ontology analysis and their associated q-value and fold-467 
change values.   468 
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 Cells and viruses. Vero E6 (CRL-1586, American Type Culture Collection (ATCC), Vero 470 
CCL81 (ATCC), and Vero-furin cells42 were cultured at 37°C in Dulbecco’s Modified Eagle 471 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM 472 
sodium pyruvate, 1× non-essential amino acids, and 100 U/ml of penicillin–streptomycin. The 473 
2019n-CoV/USA_WA1/2019 isolate of SARS-CoV-2 was obtained from the US Centers for 474 
Disease Control (CDC). Infectious stocks were grown by inoculating Vero CCL81 cells and 475 
collecting supernatant upon observation of cytopathic effect; debris was removed by 476 
centrifugation and passage through a 0.22 μm filter. Supernatant was then aliquoted and stored 477 
at -80oC.  478 
Biosafety. All aspects of this study were approved by the office of Environmental Health 479 
and Safety at Washington University School of Medicine prior to the initiation of this study. Work 480 
with SARS-CoV-2 was performed in a BSL-3 laboratory by personnel equipped with powered air 481 
purifying respirators.  482 
Mice. Animal studies were carried out in accordance with the recommendations in the 483 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The 484 
protocols were approved by the Institutional Animal Care and Use Committee at the Washington 485 
University School of Medicine (assurance number A3381–01). Virus inoculations were performed 486 
under anesthesia that was induced and maintained with ketamine hydrochloride and xylazine, 487 
and all efforts were made to minimize animal suffering. 488 
Heterozygous K18-hACE c57BL/6J mice (strain: 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) were 489 
obtained from The Jackson Laboratory. Animals were housed in groups and fed standard chow 490 
diets. Mice of different ages and both sexes were administered 2.5 x 104 PFU of SARS-CoV-2 via 491 
intranasal administration.  492 
 Plaque forming assay. Vero-furin cells42 were seeded at a density of 2.5×105 cells per 493 
well in flat-bottom 12-well tissue culture plates. The following day, media was removed and 494 
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replaced with 200 μL of 10-fold serial dilutions of the material to be titered, diluted in DMEM+2% 495 
FBS. One hours later, 1 mL of methylcellulose overlay was added. Plates were incubated for 72 496 
hours, then fixed with 4% paraformaldehyde (final concentration) in phosphate-buffered saline for 497 
20 minutes. Plates were stained with 0.05% (w/v) crystal violet in 20% methanol and washed 498 
twice with distilled, deionized H20.  499 
Measurement of viral burden and hACE2 expression. Tissues were weighed and 500 
homogenized with zirconia beads in a MagNA Lyser instrument (Roche Life Science) in 1000 μL 501 
of DMEM media supplemented with 2% heat-inactivated FBS. Tissue homogenates were clarified 502 
by centrifugation at 10,000 rpm for 5 min and stored at −80°C. RNA was extracted using the 503 
MagMax mirVana Total RNA isolation kit (Thermo Scientific) on the Kingfisher Flex extraction 504 
robot (Thermo Scientific). RNA was reverse transcribed and amplified using the TaqMan RNA-to-505 
CT 1-Step Kit (ThermoFisher). Reverse transcription was carried out at 48°C for 15 min followed 506 
by 2 min at 95°C. Amplification was accomplished over 50 cycles as follows: 95°C for 15 s and 507 
60°C for 1 min. Copies of SARS-CoV-2 N gene RNA in samples were determined using a 508 
previously published assay8. Briefly, a TaqMan assay was designed to target a highly conserved 509 
region of the N gene (Forward primer: ATGCTGCAATCGTGCTACAA; Reverse primer: 510 
GACTGCCGCCTCTGCTC; Probe: /56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/). 511 
This region was included in an RNA standard to allow for copy number determination down to 10 512 
copies per reaction. The reaction mixture contained final concentrations of primers and probe of 513 
500 and 100 nM, respectively. 514 
For hACE2 expression, RNA was DNase-treated (Thermo Scientific) following the 515 
manufacturer’s protocol. RNA levels were quantified as described above with the primer/probe 516 
set for hACE2 (IDT assay: Hs.PT.58.27645939), compared to an RNA standard curve, and 517 
normalized to mg of tissue. 518 
Cytokine and chemokine mRNA measurements. RNA was isolated from lung 519 
homogenates as described above. cDNA was synthesized from DNAse-treated RNA using the 520 
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High-Capacity cDNA Reverse Transcription kit (Thermo Scientific) with the addition of RNase 521 
inhibitor following the manufacturer’s protocol. Cytokine and chemokine expression was 522 
determined using TaqMan Fast Universal PCR master mix (Thermo Scientific) with commercial 523 
primers/probe sets specific for IFN-g (IDT: Mm.PT.58.41769240), IL-6 (Mm.PT.58.10005566), IL-524 
1b (Mm.PT.58.41616450), TNF-a (Mm.PT.58.12575861), CXCL10 (Mm.PT.58.43575827), CCL2 525 
(Mm.PT.58.42151692), CCL5 (Mm.PT.58.43548565), CXCL11 (Mm.PT.58.10773148.g), IFN-b 526 
(Mm.PT.58.30132453.g), and IL-28a/b (Thermo Scientific Mm04204156_gH) and results were 527 
normalized to GAPDH (Mm.PT.39a.1) levels. Fold change was determined using the 2-DDCt 528 
method comparing treated mice to naïve controls.  529 
 Cytokine and chemokine protein measurements. Lung homogenates were incubated 530 
with Triton-X-100 (1% final concentration) for 1 h at room temperature to inactivate SARS-CoV-531 
2. Homogenates then were analyzed for cytokines and chemokines by Eve Technologies 532 
Corporation (Calgary, AB, Canada) using their Mouse Cytokine Array / Chemokine Array 44-Plex 533 
(MD44) platform.  534 
Histology and RNA in situ hybridization. Animals were euthanized before harvest and 535 
fixation of tissues. The left lung was first tied off at the left main bronchus and collected for viral 536 
RNA analysis. The right lung then was inflated with ~1.2 mL of 10% neutral buffered formalin 537 
using a 3-mL syringe and catheter inserted into the trachea. For harvesting of brains for fixation, 538 
the mouse was decapitated, and the skull cap removed. The whole brain was removed intact, cut 539 
mid-sagittally to increase surface area of fixation, and drop fixed in 10% neutral-buffered formalin 540 
(NBF). For kidney, spleen, liver, and heart, organs were removed and drop-fixed in 10% NBF. For 541 
fixation after infection, organs were kept in a 40-mL suspension of NBF for 7 days before further 542 
processing. Tissues were embedded in paraffin, and sections were stained with hematoxylin and 543 
eosin. RNA in situ hybridization was performed using the RNAscope 2.5 HD Assay (Brown Kit) 544 
according to the manufacturer’s instructions (Advanced Cell Diagnostics). Briefly, sections were 545 
deparaffinized, treated with H2O2 and Protease Plus prior to probe hybridization. Probes 546 
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specifically targeting hACE2 (cat no. 848151) or SARS-CoV-2 S sequence (cat no 848561) were 547 
hybridized followed by proprietary signal amplification and detection with 3,3'-Diaminobenzidine. 548 
Tissues were counterstained with Gill’s hematoxylin. An uninfected mouse was used as a 549 
negative control and stained in parallel. Tissue sections were visualized using a Nikon Eclipse 550 
microscope equipped with an Olympus DP71 camera, a Leica DM6B microscope equipped with 551 
a Leica DFC7000T camera, or an Olympus BX51 microscope with attached camera.  552 
 Flow cytometry analysis of immune cell infiltrates. For analysis of BAL fluid, mice 553 
were sacrificed by ketamine overdose, followed by cannulation of the trachea with a 19-G canula. 554 
BAL was performed with three washes of 0.8 ml of sterile PBS. BAL fluid was centrifuged, and 555 
single cell suspensions were generated for staining. For analysis of lung tissue, mice were 556 
perfused with sterile PBS and the right inferior lung lobes were digested at 37°C with 630 µg/ml 557 
collagenase D (Roche) and 75 U/ml DNase I (Sigma) for 2 hours. Single cell suspensions of BAL 558 
and lung digests were preincubated with Fc Block antibody (BD PharMingen) in PBS + 2% heat-559 
inactivated FBS for 10 min at room temperature before staining. Cells were incubated with 560 
antibodies against the following markers: AF700 anti-CD45 (clone 30 F-11), APC-Cy7 anti-CD11c 561 
(clone N418), PE anti-Siglec F (clone E50-2440; BD), PE-Cy7 anti-Ly6G (clone 1A8), BV605 anti-562 
Ly6C (clone HK1.4; Biolegend), BV 711 anti-CD11b (clone M1/70), APC anti-CD103 (clone 2E7; 563 
eBioscience), PB anti-CD3 (clone 17A2), PE-Cy7, APC anti-CD4 (clone RM4-5), PE-Cy7 anti-564 
CD8 (clone53-6.7), anti-NK1.1 (clone PK136), and BV605 anti-TCR γ/δ (clone GL3). All 565 
antibodies were used at a dilution of 1:200. Cells were stained for 20 min at 4°C, washed, fixed 566 
and permeabilized for intracellular staining with Foxp3/Transcription Factor Staining Buffer Set 567 
(eBioscience) according to manufacturer’s instructions. Cells were incubated overnight at 4°C 568 
with PE-Cy5 anti-Foxp3 (clone FJK-16s), washed, re-fixed with 4% PFA (EMS) for 20 min and 569 
resuspended in permeabilization buffer. Absolute cell counts were determined using TruCount 570 
beads (BD). Flow cytometry data were acquired on a cytometer (BD-X20; BD Biosciences) and 571 
analyzed using FlowJo software (Tree Star).  572 
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Clinical laboratory analysis. Testing was performed on fresh whole-blood samples 573 
within a biosafety cabinet using point-of-care instruments. Prothrombin time was measured using 574 
the Coagucheck (Roche) meter. Electrolyte, acid-base, and hematology parameters were 575 
assayed on lithium-heparinized whole blood using the iSTAT-1 (Abbot) with the Chem8+ 576 
cartridge. 577 
 Respiratory mechanics. Mice were anesthetized with ketamine/xylazine (100 mg/kg and 578 
10 mg/kg, i.p., respectively). The trachea was isolated via dissection of the neck area and 579 
cannulated using an 18-gauge blunt metal cannula (typical resistance of 0.18 cmH2O.s/mL), which 580 
was secured in place with a nylon suture. The mouse then was connected to the flexiVent 581 
computer-controlled piston ventilator (SCIREQ Inc.) via the cannula, which was attached to the 582 
FX adaptor Y-tubing. Mechanical ventilation was initiated, and mice were given an additional 100 583 
mg/kg of ketamine and 0.1 mg/mouse of the paralytic pancuronium bromide via intraperitoneal 584 
route to prevent breathing efforts against the ventilator and during measurements. Mice were 585 
ventilated using default settings for mice, which consisted in a positive end expiratory pressure at 586 
3 cm H2O, a 10 mL/kg tidal volume (Vt), a respiratory rate  at 150 breaths per minute (bpm), and 587 
an fraction of inspired oxygen (FiO2) of 0.21 (i.e., room air). Respiratory mechanics were assessed 588 
using the forced oscillation technique, as previously described43, using the latest version of the 589 
flexiVent operating software (flexiWare v8.1.3). Pressure-volume loops and measurements of 590 
inspiratory capacity were also done. 591 
 Treadmill stress test. A six-lane mouse treadmill (Columbus Instruments, Columbus OH) 592 
was placed within a biosafety cabinet within the ABSL-3 laboratory. Mice were introduced to the 593 
treadmill test three times prior to infection, with each introductory session performed at 594 
increasingly faster rates. In general, the treadmill was set to ramp from 0 to maximum speed over 595 
the course of the first minute, then maintain maximum speed for 5 min. Failure to maintain 596 
adequate speed resulted in delivery of a shock; this occurred until the animal reinguaged the 597 
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treadmill for a maximum of 5 failures. For each sex, we identified a speed at which >80% of mice 598 
successfully completed the test prior to infection (16 m/s for female; 14 m/s for male).  599 
RNA sequencing. cDNA libraries were constructed starting with 10 ng of total RNA from 600 
lung tissues of each sample that was extracted using a MagMax mirVana Total RNA isolation kit 601 
(Thermo Scientific). cDNA was generated using the Seqplex kit (Sigma-Aldrich) with amplification 602 
of 20 cycles. Library construction was performed using 100 ng of cDNA undergoing end repair, A 603 
tailing, ligation of universal TruSeq adapters and amplification of 8 cycles to incorporate unique 604 
dual index sequences. Libraries were sequenced on the NovaSeq 6000 (Illumina, San Diego, CA) 605 
targeting 40 million read pairs and extending 150 cycles with paired end reads. RNA-seq reads 606 
were aligned to the mouse Ensembl GRCh38.76 primary assembly and SARS-CoV-2 NCBI 607 
NC_045512 Wuhan-Hu-1 genome with STAR program (version 2.5.1a)44. Gene counts were 608 
derived from the number of uniquely aligned unambiguous reads by Subread:featureCount 609 
(version 1.4.6-p5)45. The ribosomal fraction, known junction saturation, and read distribution over 610 
known gene models were quantified with RSeQC (version 2.6.2)46. All gene counts were 611 
preprocessed with the R package EdgeR47 to adjust samples for differences in library size using 612 
the trimmed mean of M values (TMM) normalization procedure. Ribosomal genes and genes not 613 
expressed at a level greater than or equal to 1 count per million reads in the smallest group size 614 
were excluded from further analysis. The R package limma48 with voomWithQualityWeights 615 
function49 was utilized to calculate the weighted likelihoods for all samples, based on the observed 616 
mean-variance relationship of every gene and sample. Differentially expressed genes were 617 
defined as those with at least 2-fold difference between two individual groups at the Benjamini-618 
Hochberg false-discovery rate (FDR) adjusted p-value, i.e. q-value < 0.05. 619 
Statistical analysis Statistical significance was assigned when P values were < 0.05 620 
using Prism Version 8 (GraphPad) and specific tests are indicated in the Figure legends. Analysis 621 
of weight change was determined by two-way ANOVA. Changes in functional parameters or 622 
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immune parameters were compared to mock-infected animals and were analyzed by one-way 623 
ANOVA or one-way ANOVA with Dunnett’s test.  624 
Data availability. All data supporting the findings of this study are found within the paper 625 
and its Extended Data Figures, and are available from the corresponding author upon request. 626 
RNA sequencing data sets generated in this study are available at GEO: GSE154104.  627 
  628 
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